Continuous subcutaneous insulin infusion (CSII) therapy using insulin infusion pumps has been used for over 20 years. 1, 2 The early mechanical insulin pumps of the last century were fraught with problems which included mechanical breakdowns, blocked cannulas and an increased incidence of ketoacidosis. between CSII use and the ability of the healthcare network to support the additional costs. CSII is an expensive alternative to multiple daily injections and will raise the cost of diabetes management significantly. 8 Its use is limited to wealthy patients or those on medical schemes which agree to reimburse the cost of the pump therapy. Thus, the benefits of CSII should be measurable and demonstrable.
Creation of an environment in which these benefits can be realised will ensure the viability and sustainability of this form of therapy in the diabetes care armamentarium.
With the progressive sophistication of insulin pumps and the introduction of continuous glucose montoring devices, either independent of or linked to the pumps themselves, the need for highly trained individuals to supervise and council patients on CSII is becoming increasingly obvious. For these reasons, CSII should only be initiated and managed by a centre which has the required expertise and trained staff, as outlined and specified in the pump guidelines. Therefore, prospective insulin pump patients should be referred to a local pump centre for evaluation, initiation and ongoing management of insulin pump therapy should CSII therapy be deemed to be appropriate. 
Conclusion
The advent of newer designer basal analogue insulins, ultra-rapid acting insulin analogues, pen devices and 4-mm needles will continue to erode the absolute haemoglobin 
